Here are 1-3 brief analogies for electroCore (ECOR):

• ResMed for migraine and cluster headache devices.
• Medtronic for non-invasive headache treatments.

• gammaCore: A prescription-only non-invasive vagus nerve stimulation (nVNS) therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
• gammaCore Sapphire: A rechargeable and reloadable handheld device that delivers the gammaCore nVNS therapy.

• Benchmark Electronics, Inc. (BHE)
• Zynex Medical, Inc. (ZYXI)

Daniel S. Goldberger, Chief Executive Officer

Daniel S. Goldberger has over 35 years of leadership and medical device experience. Prior to joining electroCore, he served as Executive Chairman, Chairman, and interim Chief Executive Officer of Repro Med Systems, Inc. (RMS). He also held positions as Director and Chief Executive Officer of Xtant Medical Holdings, Inc. and Director and Chief Executive Officer of Sound Surgical Technologies. Earlier in his career, he held various positions at Glucon, Inc., OSI Systems, Ohmeda, Nellcor, and Hewlett Packard. Goldberger is recognized for his expertise in turnarounds, commercial execution, capital formation, and product development across diverse medical technology companies.

Joshua Lev, Chief Financial Officer

Joshua Lev was appointed Chief Financial Officer of electroCore, effective October 4, 2024. He previously served as Chief Strategy Officer for the company since January 2022, and as VP of Business Development, Strategy, and Financial Planning since February 2020. Before joining electroCore, Mr. Lev accumulated over 15 years of experience in the financial services industry as an investment banker and investor, focusing on emerging growth companies. He was a co-founder of Aracle Capital, LLC from March 2014 through February 2020, and served as Director of Business Development at Wellfleet Partners, Inc. from 2011 to February 2020, where he focused on capital raising, M&A, and strategic transactions.

Peter S. Staats, MD, MBA, Chief Medical Officer

Dr. Peter Staats is a co-founder of electroCore and is responsible for overseeing the clinical development of gammaCoreTM. He previously served on the company's board of directors. Dr. Staats is internationally recognized for his work in neuromodulation strategies and minimally invasive procedures for chronic pain, and he founded the Division of Pain Medicine at Johns Hopkins University, where he served as director for 10 years.

Manny Marques, Senior Vice President, Operations

Manny Marques serves as the Senior Vice President of Operations for electroCore.

Mitch DeShon, Vice President Global Sales & Business Development

Mitch DeShon has over 20 years of experience in the medical device industry. He has held executive sales and business development roles at companies such as Sound Surgical, ICN Pharmaceuticals, ESC/Lumenis, and Sherwood Medical. Prior to electroCore, he was the Vice President of Sales for Venus Concept, managing the Australia/APAC region.

Here are the key risks to electroCore's business:

1. Dependence on Additional Funding and Path to Profitability: electroCore is currently unprofitable and continues to incur net losses, requiring the company to raise additional capital to fund its ongoing operations, product development, and commercialization strategies. Despite some revenue growth, the company's widening net loss and negative operating cash flow indicate a persistent cash burn that necessitates significant revenue increases to achieve cash flow positivity and long-term financial stability.

2. High Customer Concentration and Reliance on the VA Channel: A substantial portion of electroCore's revenue, particularly within its prescription device segment, is generated through the U.S. Department of Veterans Affairs (VA) channel. For instance, the VA channel accounted for approximately 70% of total revenue in Q2 2025 and 70.6% in 2024. This heavy dependence on a single customer channel exposes the company to significant risk, as any adverse changes in VA procurement policies, reimbursement rates, or budget allocations could severely destabilize its financial model.

3. Reimbursement Challenges and Market Adoption: While electroCore's products, such as gammaCore, have received regulatory clearances, the company faces ongoing hurdles in securing widespread and adequate reimbursement from both governmental payers (like the Centers for Medicare and Medicaid Services, CMS) and private insurance providers. Decisions from entities like CMS have historically rejected appeals for higher payment amounts, limiting the commercial viability of its novel medical devices. Slow market penetration and challenges in establishing broad reimbursement can hinder patient access and overall revenue growth for its non-invasive vagus nerve stimulation (nVNS) therapies.

electroCore, Inc. (ECOR) develops and commercializes gammaCore, a non-invasive vagus nerve stimulation (nVNS) therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults, and for the preventive treatment of cluster headache and migraine in adults.

The addressable markets for electroCore's main products and services are as follows:

Migraine Market

• Global Market: The global migraine drugs market was valued at approximately USD 10.88 billion across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) in 2023 and is projected to increase through 2034. Other estimates for the global migraine drugs market include a valuation of USD 6.81 billion in 2024, projected to reach USD 13.34 billion by 2030, growing at a CAGR of 10.9%. Another source valued the global market at USD 7.67 billion in 2025, projected to grow to USD 19.71 billion by 2034, exhibiting a CAGR of 11.06%.
• U.S. Market: The U.S. migraine market accounted for approximately USD 6.79 billion in 2023, making it the highest among the 7MM. The U.S. migraine drugs market generated a revenue of USD 2.937 billion in 2024 and is expected to reach USD 6.1712 billion by 2030, growing at a CAGR of 13.2% from 2025 to 2030.

Cluster Headache Market

• Global Market: The global cluster headache market was valued at approximately USD 456.6 million in 2024 and is projected to reach USD 899.8 million by 2035, expanding at a CAGR of 6.4% from 2025 to 2035. Another report estimated the global market to be valued at USD 449.3 million in 2025 and expected to reach USD 694.0 million by 2032, exhibiting a CAGR of 6.4%.
• U.S. Market: The total cluster headache treatment market size across the 7MM (US, EU4, UK, and Japan) was around USD 890 million in 2023. The U.S. captured the highest share of this market, approximately USD 467 million in 2023. North America, specifically, held a dominant market share of 41.7% in the global cluster headache market in 2025, with the U.S. being a significant contributor due to its developed healthcare infrastructure.

electroCore (ECOR) is anticipated to drive future revenue growth over the next two to three years through several key initiatives:

• Expansion within the U.S. Prescription Channel, particularly the VA Hospital System: The company has seen continued growth in prescription device sales for both gammaCore and the newly acquired Quell Fibromyalgia product within the Department of Veteran Affairs (VA) hospital system. Management is strategically investing in strengthening the VA and managed-care channels to further accelerate this growth.
• Growth of the Truvaga Wellness Product Line and AI-Enabled Software Strategy: Truvaga wellness sales have demonstrated significant year-over-year increases, with the company actively increasing its media budget to drive further growth in this direct-to-consumer channel. Additionally, electroCore is developing a next-generation AI-enabled app for Truvaga to foster recurring revenue.
• Synergy and Expansion from the NeuroMetrix (Quell) Acquisition: The acquisition of NeuroMetrix, including the Quell Fibromyalgia product, is already exceeding expectations and contributing to revenue, particularly within the VA channel. electroCore also plans to launch additional health and wellness offerings, such as Quell Relief for lower extremity pain, leveraging this acquisition.
• International Market Expansion and Reimbursement Gains: electroCore is pursuing commercialization in new international markets, including a planned royalty arrangement for China. The company has also secured long-term reimbursement approval for gammaCore in Belgium and has plans for expansion into Canada and the UK, broadening its global footprint.
• Development of New Use Cases and Target Demographics for nVNS Products: The company expects to introduce new applications and target populations for its non-invasive vagus nerve stimulation (nVNS) products. This includes exploring adjunctive treatment for symptoms associated with Post-Traumatic Stress Disorder (PTSD) using gammaCore Sapphire.

Share Issuance

• In June 2024, electroCore closed a registered direct offering and concurrent private placements, generating approximately $9.3 million in gross proceeds. These funds were intended for sales and marketing, working capital, and general corporate purposes.
• Approximately $5.645 million of the gross proceeds from the June 2024 offering were provided by directors and officers of electroCore.
• In October 2025, electroCore issued 360,737 shares in a private placement, valued at approximately $1.856 million, to satisfy outstanding legal fee obligations, with no cash proceeds received by the company.

Inbound Investments

• Directors and officers of electroCore provided approximately $5.645 million as part of the $9.3 million gross proceeds raised in a June 2024 offering.
• In October 2025, electroCore issued 106,351 private placement shares to "Avenue" in connection with a loan agreement.

Outbound Investments

• In the third quarter of 2025, electroCore completed a strategic acquisition of NeuroMetrix, which brought the Quell portfolio of products, including Quell Fibromyalgia.

Capital Expenditures

• Specific dollar values for traditional capital expenditures over the last 3-5 years are not readily available in the provided information.
• The company has focused on targeted investments in sales and marketing to support commercial efforts, as noted in Q2 and Q3 2025.
• Increased development costs associated with a next-generation mobile application were reported in the third quarter of 2025, indicating investment in research and development.